Nuclidium: Funding, Investors & Team (Sep 2026)
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Nuclidium has raised $33.6M across 1 funding round on record, the most recent a Series B of $33.6M announced in May 2026.
That round is above the $4.8M median round size for Health Care companies tracked on FundedIQ over the last two years.
Nuclidium Company Profile and Key Stats
Latest funding round on record: May 2026.
Nuclidium Funding Rounds
Nuclidium Founders and Leadership Team
Contact details for the Nuclidium team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Nuclidium Funding Compared to Other Health Care Startups
Nuclidium's latest round of $33.6M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nuclidium in Health Care and Basel
Companies Similar to Nuclidium
MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.
CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin…
Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify…
UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva)…
Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond…
Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of…
Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment…
Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of…
Vivent provides growers, breeders and agrochem companies with actionable information direct from plants…
Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded…
Qumea provides a unique solution for discreet patient monitoring. By fusing AI and 3D radar technology, QUMEA…
Nuclidium Funding FAQs
What does Nuclidium do?
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
How much funding has Nuclidium raised?
Nuclidium has raised $33.6M across 1 round on record. The most recent is a Series B of $33.6M announced in May 2026.
When did Nuclidium last raise funding?
Nuclidium's most recent funding round on record is a Series B of $33.6M, announced in May 2026.
Who founded Nuclidium?
FundedIQ lists Leila Jaafar (Founder) at Nuclidium.
Where is Nuclidium headquartered?
Nuclidium is based in Basel, Basel-Stadt, Switzerland.
How many employees does Nuclidium have?
Nuclidium is in the 11-50 employee band.
How does Nuclidium's funding compare to other Health Care startups?
Nuclidium's latest round of $33.6M is above the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Nuclidium Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nuclidium is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.